This phase III study is for patients with newly diagnosed symptomatic multiple myeloma. It compares two combinations of drugs to see which works better as induction treatment.Then, the study’s primary goal is to study the maintenance treatment given after induction treatment. It compares whether continuing maintenance treatment with the immunotherapy drug lenalidomide until the cancer returns is better than stopping lenalidomide maintenance treatment after 2 years.
DIA MUNDIAL DE LA RETINOSIS PIGMENTARIA
Hace 1 hora